ArticleTranslational oncology2026
Identification of CTHRC1 as a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma by Bioinformatics Analysis.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) carries one of the highest case-fatality rates among gastrointestinal malignancies, owing in part to the scarcity of molecularly validated prognostic indicators. Collagen triple helix repeat containing 1 (CTHRC1), a secreted glycoprotein implicated in matrix remodeling across multiple tumor types, has yet to be systematically interrogated in ESCC. The present investigation aims to define the prognostic relevance of CTHRC1 in ESCC through a multi-layered bioinformatics framework.
methodsTranscriptomic profiles from the TCGA-ESCA project and two independent GEO cohorts (GSE53624, GSE23400) were leveraged to quantify CTHRC1 abundance relative to normal esophageal mucosa. Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) mapping were applied to delineate CTHRC1-centric functional modules and molecular interaction hubs. Single-cell RNA sequencing (scRNA-seq) data from GSE160269 were interrogated to resolve cell-type-specific CTHRC1 distribution within the tumor ecosystem. Prognostic relevance was appraised via Kaplan-Meier survival curves, Cox regression, and time-dependent ROC analysis. Experimental corroboration was obtained by qRT-PCR and immunofluorescence (IF) in a panel of ESCC lines (EC109, KYSE-150, KYSE-30, TE-1) and primary cancer-associated fibroblasts (CAFs), supplemented by CTHRC1 loss- and gain-of-function manipulation in KYSE-30.
resultsAcross all three genomic cohorts, CTHRC1 transcripts were markedly elevated in tumor versus matched normal tissue (p < 0.001). WGCNA assigned CTHRC1 to a gene module enriched for extracellular matrix (ECM) organization, epithelial-mesenchymal transition (EMT), and invasive signaling, while PPI mapping disclosed functional links to collagen family members and matrix metalloproteinases. Single-cell profiling localized peak CTHRC1 activity to cancer-associated fibroblasts and a defined subset of malignant epithelial cells. Clinically, elevated CTHRC1 tracked with higher T and N classifications and advanced pathological stage; high expressors faced substantially inferior overall survival (multivariate-adjusted hazard ratio = 1.78, 95% CI: 1.23-2.57, p = 0.002), with multivariate Cox analysis confirming its independence from conventional staging parameters. In vitro, qRT-PCR revealed 4.8-8.5-fold CTHRC1 mRNA enrichment across all four ESCC lines relative to HEEC (p < 0.001). IF experiments demonstrated cancer-restricted CTHRC1-Pan-CK co-localization, CTHRC1-dependent modulation of Vimentin and MMP9 abundance, and selective CTHRC1-α-SMA co-expression in myofibroblastic CAFs.
conclusionsIntegrative multi-omics interrogation nominates CTHRC1 as a reproducibly overexpressed, clinically actionable prognostic molecule in ESCC. Its tight coupling to ECM remodeling pathways, tumor-stromal crosstalk, and unfavorable survival outcomes positions CTHRC1 as a candidate for risk-stratification algorithms and targeted therapeutic development. Prospective multi-center validation and mechanistic dissection in vivo remain essential next steps toward clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.